Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

To Study Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03975374
Recruitment Status : Not yet recruiting
First Posted : June 5, 2019
Last Update Posted : June 5, 2019
Information provided by (Responsible Party):
Dr. Ajai Prakash, Sutphin Drugs

Brief Summary:
The objective of the study is to compare and describe efficacy and safety of Tobradex ophthalmic suspension versus generic Tobramycin/dexamethasone Suspension in treatment of Blepharoconjuctivitis through clinical parameters

Condition or disease Intervention/treatment Phase
Blepharo Conjunctivitis Drug: Tobramycin/dexamethasone opthalmic solution Drug: Tobradex Opthalmic Solution Early Phase 1

Detailed Description:
Evaluation of signs and symptoms during treatment, with a record of individual scores for each parameter; Observation and statistical comparison of drug safety, by recording qualitative and quantitative parameters related to adverse effects occurring during treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 5000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

In group one, patients will be instructed to instill 2 gtt of Tobradex ophthalmic solution for 10 days.

In group two, patients will be instructed to instill 2 gtt of Tobramycin/dexamethasone solution for 10 days .

Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Tobradex Eye Drop Suspension vs Tobramycin/Dexamethasone Ophthalmic Suspension
Estimated Study Start Date : June 15, 2019
Estimated Primary Completion Date : July 1, 2019
Estimated Study Completion Date : June 30, 2020

Arm Intervention/treatment
Experimental: Tobramycin/Dexamethasone opthamic Solution
This group of randomized patients will be instructed to instill 2 gtt of Tobramycin/Dexamethasone opthamic solution every 6 hours for 10 days
Drug: Tobramycin/dexamethasone opthalmic solution
To compare efficacy and safety in randomized patients recieving Tobradex versus Tobramycin/Dexamethasone opthamic Solution
Other Name: Tobradex

Active Comparator: Tobradex Opthalmic Solution
This group of randomized patients will be instructed to instill 2 gtt of Tobradex Opthalmic Solution every 6 hours for 10 days
Drug: Tobradex Opthalmic Solution
Tobradex Opthalmic Solution

Primary Outcome Measures :
  1. Sign and symptoms composite score [ Time Frame: 10 days ]

    The change from baseline in the signs and symptoms score. Global sign and symptom score defined as the total score of lid margin redness (0-3), lid swelling (0-4), bulbar conjunctival redness (0-3), palpebral conjunctival redness (0-3), ocular discharge (0-3), itchy eyelids (0-4), and gritty eyes (0-4).

    The change from baseline to Day 10 (Visit 3 at day 1, day 7 and day 10) in the ocular signs and symptoms composite score. Ocular signs and symptoms were collected for study eyes at each study visit using a 0-4 grading scale, assessed as 0 = none, 1 = minimal/trace, 2 = mild, 3 = moderate, and 4 = severe. The signs and symptoms composite score was the sum of each individual sign or symptom score.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All potential subjects with symptomatic blepharitis examined to have blepharitis with healthy mental status, able to give consent, with/without co-existing medical conditions will be considered

Exclusion Criteria:

  • All subjects with history and/or probable history of allergic reaction to tobramycin/dexamethasone and all subjects who have mental disability and are unable to give direct consent will be excluded

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03975374

Layout table for location contacts
Contact: Ajai Prakash 7183260310
Contact: Jayesh R patel 5166414687

Layout table for location information
United States, New York
Sutphin Drugs
Jamaica, New York, United States, 11435
Contact: Ajai Prakash, PhD    718-326-0310   
Contact: Jayesh Patel    5166414687   
Sponsors and Collaborators
Sutphin Drugs
Layout table for investigator information
Principal Investigator: Ajai Prakash Sutphin Drugs

Layout table for additonal information
Responsible Party: Dr. Ajai Prakash, President, Sutphin Drugs Identifier: NCT03975374    
Other Study ID Numbers: Sutphin T
First Posted: June 5, 2019    Key Record Dates
Last Update Posted: June 5, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Conjunctival Diseases
Eye Diseases
Tobramycin, Dexamethasone Drug Combination
Dexamethasone acetate
Ophthalmic Solutions
Pharmaceutical Solutions
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents